# SPARTAN (NCT01946204)

> A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT01946204
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Aragon Pharmaceuticals, Inc.
- Conditions: Prostatic Neoplasms
- Interventions: Apalutamide; Placebo
- Enrollment: 1207
- Primary outcome: Metastasis-Free Survival (MFS) by Blinded Independent Central Review (BICR)

## Indexed commentary on SPARTAN so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=spartan-nct01946204